November 1, 2017

Tamoxifen Therapy Benefit for Patients with 70-gene Signature High and Low Risk

PUBLICATION: 
Breast Cancer Res Treat (2017) 166: 593. https://doi.org/10.1007/s10549-017-4428-9.

AUTHORS: 
Laura J. van ‘t Veer, Christina Yau, Nancy Y. Yu, Christopher C. Benz, Bo Nordenskjöld, Tommy Fornander, Olle Stål, Laura J. Esserman, Linda Sofie Lindström

SUMMARY: 
20yr BCSS and 10yr DMFS analysis of MammaPrint High Risk vs Low Risk patients in the STO trial.

Read more: van’t Veer et al_2017_Breast Cancer Research and Treatment_Tamoxifen Therapy Benefit…